Suppr超能文献

感染性主动脉移植物原位假体置换的结果。

The results of in situ prosthetic replacement for infected aortic grafts.

作者信息

Young R M, Cherry K J, Davis P M, Gloviczki P, Bower T C, Panneton J M, Hallett J W

机构信息

Mayo Clinic, Rochester, Minnesota 55905, USA.

出版信息

Am J Surg. 1999 Aug;178(2):136-40. doi: 10.1016/s0002-9610(99)00146-4.

Abstract

BACKGROUND

Treatment of aortic graft infection with graft excision and axillofemoral bypass may carry an increased risk of limb loss, aortic stump blowout, and pelvic ischemia. A review of patients with aortic graft infection treated with in situ prosthetic graft replacement was undertaken to determine if mortality, limb loss, and reinfection rates were improved with this technique.

METHODS

The clinical data of 25 patients, 19 males and 6 females, with a mean age of 68 years (range 35 to 83), with aortic graft infection, treated between January 1, 1989, and December 31, 1998, by in situ prosthetic graft replacement were reviewed. Follow-up was complete in the 23 surviving patients and averaged 36 months (range 4 to 103).

RESULTS

Twenty aortofemoral, 3 aortoiliac, and 2 straight aortic graft infections were treated with excision and in situ replacement with standard polyester grafts in 16 patients (64%), or with rifampin-soaked collagen or gelatin-impregnated polyester grafts in 9 patients (36%). Fifteen patients (60%) had aortic graft enteric fistulas, 8 patients (32%) had abscesses or draining sinuses, and 2 patients (8%) had bacterial biofilm infections. Thirty-day mortality was 8% (2 of 25). There were no early graft occlusions or amputations. There was one late graft occlusion. There were no late amputations. The reinfection rate was 22% (5 grafts). All reinfections occurred in patients operated upon for occlusive disease. Only one reinfection occurred in the rifampin-soaked graft group (11% versus 29%, P = NS). Reinfection tended to be lower in patients with aortoenteric fistulas and without abscess. Autogenous tissue coverage provided statistically significant protection against reinfection. There were no late deaths related to in situ graft infection.

CONCLUSIONS

Patients treated with in situ graft replacement had an 8% mortality and 100% limb salvage rate. Reinfection rates were similar to those of extra-anatomic bypass, but a trend of lower reinfection rates with rifampin-impregnated grafts was apparent. Patients with aortoenteric fistula and without abscess appear to be well treated by the technique of in situ prosthetic grafting and autogenous tissue coverage.

摘要

背景

采用移植物切除及腋股动脉旁路移植术治疗主动脉移植物感染可能会增加肢体丧失、主动脉残端破裂及盆腔缺血的风险。我们对采用原位人工血管置换术治疗的主动脉移植物感染患者进行了一项回顾性研究,以确定该技术是否能改善死亡率、肢体丧失率及再感染率。

方法

回顾了1989年1月1日至1998年12月31日期间采用原位人工血管置换术治疗的25例主动脉移植物感染患者的临床资料,其中男性19例,女性6例,平均年龄68岁(35至83岁)。23例存活患者均完成随访,平均随访时间为36个月(4至103个月)。

结果

20例为主动脉股动脉移植物感染,3例为主动脉髂动脉移植物感染,2例为直主动脉移植物感染。16例患者(64%)采用切除并原位置换标准聚酯人工血管治疗,9例患者(36%)采用含利福平的胶原或明胶浸渍聚酯人工血管治疗。15例患者(60%)发生主动脉移植物肠瘘,8例患者(32%)出现脓肿或引流窦,2例患者(8%)发生细菌生物膜感染。30天死亡率为8%(25例中的2例)。无早期移植物闭塞或截肢情况。发生1例晚期移植物闭塞。无晚期截肢情况。再感染率为22%(5根移植物)。所有再感染均发生在因闭塞性疾病接受手术的患者中。含利福平的移植物组仅发生1例再感染(11%对29%,P=无显著性差异)。主动脉肠瘘且无脓肿的患者再感染率往往较低。自体组织覆盖对预防再感染具有统计学意义的保护作用。无原位移植物感染相关的晚期死亡病例。

结论

采用原位血管置换术治疗的患者死亡率为8%,肢体保全率为1〇〇%。再感染率与解剖外旁路移植术相似,但含利福平的移植物再感染率有降低趋势。主动脉肠瘘且无脓肿的患者采用原位人工血管置换术及自体组织覆盖技术治疗效果良好。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验